Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
2.230
-0.010 (-0.44%)
At close: Nov 7, 2025, 4:00 PM EST
2.406
+0.176 (7.87%)
After-hours: Nov 7, 2025, 5:44 PM EST
Tivic Health Systems Revenue
Tivic Health Systems had revenue of $86.00K in the quarter ending June 30, 2025, a decrease of -38.57%. This brings the company's revenue in the last twelve months to $462.00K, down -58.49% year-over-year. In the year 2024, Tivic Health Systems had annual revenue of $780.00K, down -33.67%.
Revenue (ttm)
$462.00K
Revenue Growth
-58.49%
P/S Ratio
2.78
Revenue / Employee
$66,000
Employees
7
Market Cap
3.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 780.00K | -396.00K | -33.67% |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | 860.00K | 440.00K | 104.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TIVC News
- 1 day ago - Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast - Business Wire
- 16 days ago - Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 - Business Wire
- 6 weeks ago - Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference - Business Wire
- 2 months ago - Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing - Business Wire
- 2 months ago - Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers - Business Wire
- 3 months ago - Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025 - Business Wire
- 3 months ago - Tivic Health Systems, Inc. (TIVC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Tivic Reports Second Quarter 2025 Financial Results - Business Wire